These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2655298)

  • 1. Propafenone: a novel type Ic antiarrhythmic agent.
    Parker RB; McCollam PL; Bauman JL
    DICP; 1989 Mar; 23(3):196-202. PubMed ID: 2655298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propafenone: an effective agent for the management of supraventricular arrhythmias.
    Grant AO
    J Cardiovasc Electrophysiol; 1996 Apr; 7(4):353-64. PubMed ID: 8777484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM; Palmer KJ; Langtry HD; Fitton A
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for the use of propafenone in treating supraventricular arrhythmias.
    Kishore AG; Camm AJ
    Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
    Ludmer PL; McGowan NE; Antman EM; Friedman PL
    J Am Coll Cardiol; 1987 Jun; 9(6):1357-63. PubMed ID: 3294970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Oct; 31(10):1227-43. PubMed ID: 9337449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study.
    Shen EN; Keung E; Huycke E; Dohrmann ML; Nguyen N; Morady F; Sung RJ
    Ann Intern Med; 1986 Nov; 105(5):655-61. PubMed ID: 3767146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
    Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
    Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
    Manz M; Steinbeck G; Lüderitz B
    Am J Cardiol; 1985 Oct; 56(10):593-7. PubMed ID: 4050693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
    Coumel P; Leclercq JF; Assayag P
    Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
    Capucci A; Boriani G
    Drug Saf; 1995 Jan; 12(1):55-72. PubMed ID: 7741984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia.
    Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R
    Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
    Circulation; 1995 Nov; 92(9):2550-7. PubMed ID: 7586356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the right drug: a treatment algorithm for regular supraventricular tachycardias.
    Lévy S; Ricard P
    Eur Heart J; 1997 May; 18 Suppl C():C27-32. PubMed ID: 9152672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis.
    Reimold SC; Maisel WH; Antman EM
    Am J Cardiol; 1998 Oct; 82(8A):66N-71N. PubMed ID: 9809903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
    Hammill SC; McLaran CJ; Wood DL; Osborn MJ; Gersh BJ; Holmes DR
    J Am Coll Cardiol; 1987 Jun; 9(6):1364-8. PubMed ID: 3584724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antiarrhythmic drugs in pediatric use: propafenone.
    Paul T; Janousek J
    Pediatr Cardiol; 1994; 15(4):190-7. PubMed ID: 7991437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
    Manz M; Beermann J; Gerckens U; Lüderitz B
    Z Kardiol; 1986 Dec; 75(12):757-63. PubMed ID: 3825226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Electrophysiologic effect of intravenous propafenone in supraventricular tachycardia].
    Iturralde P; Nunura F; Romero L; Colín L; Rosado J; Galván O; de Micheli A; González Hermosillo JA; Casanova JM
    Arch Inst Cardiol Mex; 1991; 61(2):135-41. PubMed ID: 1854228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.